The Phase 3b study found that 14% of patients receiving the modified titration experienced ARIA-E, compared to 24% in those on the standard dosing regimen, according to an Oct. 29 news release from the company. The modified approach allows for once-monthly dosing while maintaining amyloid plaque clearance.
Donanemab was approved by the FDA in July under the brand name Kinsula. Eli Lilly plans to discuss the findings with global regulators and may seek a label update for Kinsula, the release said.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
